Table 3 Multivariate analysis of the association between clinicopathological characteristics and overall survival.

From: Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations

Variables

Parameters

Total (n)

OR

95% CI

p-value

Age*

≤61 years

126

1

Ref.

Ref.

>61 years

107

1.45

1.09–1.93

0.01

Histology

Acinar

119

1

Ref.

Ref.

Mucinous

5

0.77

0.27–2.20

0.63

Lepidic

8

1.01

0.43–2.39

0.98

Papillary

27

1.22

0.76–1.97

0.41

Solid

74

1.91

1.36–2.68

<0.0001

Loss of weight**

No

105

1

Ref.

Ref.

<10%

81

1.11

0.80–1.53

0.55

>10%

47

1.72

1.17–2.54

0.006

PS ECOG

0

13

1

Ref.

Ref

1

122

1.64

0.78–3.46

0.16

2

42

2.43

1.07–5.51

0.03

3 or 4

56

6.28

2.80–14.08

<0.0001

Metastasis at diagnosis

CNS

74

1

Ref.

Ref.

Other sites

159

0.62

0.45–0.85

0.004

TKi_EGFR

Yes_WT

13

1

Ref.

Ref.

Yes_Mutated

48

0.91

0.45–1.84

0.926

No_WT

152

1.75

0.92–3.31

0.052

No_Mutated

20

3.79

1.73–8.33

0.001

KRAS mutations

WT

194

1

Ref.

Ref.

Mutated

39

2.93

1.94–4.42

<0.0001

  1. *Only patients diagnosed at stage IV were included in this analysis. n, number of patients; OR, odds ratio; 95% CI, 95% confidence interval; p-value: significance of Cox Regression; Ref., reference group; *age was categorized into two groups considering the average age of the entire series as the cutoff; **Loss of weight <10% and >10% of total body weight; PS ECOG, performance status ECOG (Eastern Cooperative Oncology Group); CNS, central nervous system; TKi_EGFR, combination of two variables (TKi treatment and EGFR mutation). Significant associations are indicated in bold.
Back to article page